Current & upcoming clinical trials - Updated 4/26/2015
Phase 1/Phase 2
April 2015 - December 2019Study type: Interventional
Phase 1 (ADXS11-001 + MEDI4736 Combination Therapy) Phase 1 will be a dose-confirmation safety run-in of ADXS11-001 and MEDI4736 combination therapy. Mandatory fresh biopsies will be obtained pre- and during treatment. Phase 2: 48 subjects will be randomized 1:1:2 to receive ADXS11-001 monotherapy, MEDI4736 monotherapy or ADXS11 001 + MEDI4736 combination therapy. Arm A: ADXS11-001 Monotherapy: Arm B: MEDI4736 Monotherapy: Arm C: ADXS11-001 + MEDI4736 combination therapy Sponsor: Advaxis, Inc.
Phase 1/Phase 2
April 2015 - August 2016Study type: Interventional
In this study, effects of ?dT cells on human breast cancer (her2-, er-,pr-) in combination with tumor reducing surgery, for example cryosurgery going to be investigated. Sponsor: Fuda Cancer Hospital, Guangzhou
April 2015 - March 2017Study type: Interventional
Background: - Some people with gastrointestinal or ovarian cancer also have ascites. That is free fluid built up in the abdomen. Researchers want to see if a new drug can affect some of the immune cells in the ascites. This may also treat the cancer. Objective: - To look at the immune markers the ascites of people with gastrointestinal or ovarian cancer. Eligibility: - Adults age 18 and older with a malignancy of the GI tract or metastatic ovarian cancer. As a result, they have ascites in the abdomen. Design: - Participants will be screened with: - Medical history, physical exam, and blood tests. - Echocardiogram: sound waves make images of the heart. - Electrocardiogram: measures electrical activity of the heart. - Paracentesis: a needle will be inserted in the abdomen and will remove some of the ascites fluid. - They may have a tumor biopsy. - Participants will get AZD9150 through a vein for 3 hours. They will get this 6 times in cycle 1 and 4 times all other cycles. Each cycle is 28 days. - Each cycle, participants will: - Have a physical exam. - Have blood tests weekly. - Be asked about how they feel and any medicines they are taking. - After every 2 cycles (about every 2 months), participants will have scans and x-rays of their tumor. - Participants will have paracentesis 2 more times during the study. They will have another echocardiogram. - At the end of therapy, participants will have a physical exam and blood tests. They will be asked about how they feel and any medicines they are taking. Sponsor: National Institutes of Health Clinical Center (CC)
April 2015 -Study type: Interventional
The goal of this clinical research study is to learn if BMN 673 can help to control breast cancer that has a BRCA mutation. The safety of BMN 673 will also be studied. Sponsor: M.D. Anderson Cancer Center
April 2015 - November 2015Study type: Interventional
This study evaluates the efficacy of a stress-focused tailored weight loss intervention compared to a standard weight loss intervention on weight loss in severely obese (BMI > 40.0) African American women. Sponsor: University of North Carolina, Chapel Hill
The information found on this site has been provided by clinicaltrials.gov in accordance with their terms & conditions. Neither we (inclinicaltrials.com), the United States Government, U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, nor any of its agencies, contractors, subcontractors or employees of the United States Government make any warranties, expressed or implied, with respect to data found on this site, and, furthermore, assume no liability, or the results of such use, of any part of the data.